EBS Stock Analysis: Emergent Biosolutions | NYSE
Drug Manufacturers - Specialty & Generic | NYSE, USA | Market Cap: 428m USD | 12M Return: 9.7% | Charts, Fundamentals & Technical Analysis
Avg Turnover: 7.28M
Qual. Beats: 0
Rev. Trend: -86.9%
Qual. Beats: 0
Warnings
Tailwinds
No distinct edge detected
Seasonality 10.5 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
Emergent BioSolutions Inc. is a Gaithersburg, Maryland-based life sciences company incorporated in 1998 that develops and supplies preparedness and response products for accidental, deliberate, and naturally occurring public health threats across the United States, Canada, and international markets. The company reports through three segments: Commercial Products, MCM (Medical Countermeasures) Products, and All Other Revenues.
Its portfolio spans vaccines (including ACAM2000 for smallpox/mpox, BioThrax for anthrax, and CYFENDUS for post-exposure anthrax prophylaxis), polyclonal antibody therapeutics (ANTHRASIL, BAT, CNJ-016), monoclonal antibodies (Ebanga for Ebola virus disease, Raxibacumab for inhalational anthrax), the oral smallpox antiviral TEMBEXA, and the NARCAN and KLOXXADO nasal sprays for emergency opioid overdose reversal.
Beyond its proprietary products, Emergent operates a contract development and manufacturing organization (CDMO) business that provides drug substance and product manufacturing, packaging, analytical and process development, technology transfer, and suite reservation services. The biodefense focus of its MCM segment relies heavily on U.S. government procurement, a business model typical of companies supplying medical countermeasures under federal contracts such as those administered through the Strategic National Stockpile.
- NARCAN margins pressured by generic OTC competition
- Government biodefense contracts drive MCM segment revenue growth
- Debt reduction and CDMO divestiture reshape capital allocation
| Net Income: -8.60m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.10 > 0.02 and ΔFCF/TA 3.64 > 1.0 |
| NWC/Revenue: 72.24% < 20% (prev 61.62%; Δ 10.61% < -1%) |
| CFO/TA 0.11 > 3% & CFO 148.0m > Net Income -8.60m |
| Net Debt (413.3m) to EBITDA (154.5m): 2.68 < 3 |
| Current Ratio: 4.29 > 1.5 & < 3 |
| Outstanding Shares: last quarter (56.5m) vs 12m ago -1.40% < -2% |
| Gross Margin: 44.44% > 18% (prev 36.43%; Δ 8.01% > 0.5%) |
| Asset Turnover: 49.28% > 50% (prev 67.70%; Δ -18.41% > 0%) |
| Interest Coverage Ratio: 1.06 > 6 (EBIT TTM 59.1m / Interest Expense TTM 55.6m) |
| A: 0.37 (Total Current Assets 637.6m - Total Current Liabilities 148.7m) / Total Assets 1.32b |
| B: -0.12 (Retained Earnings -153.0m / Total Assets 1.32b) |
| C: 0.04 (EBIT TTM 59.1m / Avg Total Assets 1.37b) |
| D: 0.66 (Book Value of Equity 523.1m / Total Liabilities 797.3m) |
| Altman-Z'' = 3.03 = A |
| DSRI: 0.85 (Receivables 121.6m/203.7m, Revenue 676.8m/965.4m) |
| GMI: 0.82 (GM 36.43% / 44.44%) |
| AQI: 1.05 (AQ_t 0.37 / AQ_t-1 0.35) |
| SGI: 0.70 (Revenue 676.8m / 965.4m) |
| TATA: -0.12 (NI -8.60m - CFO 148.0m) / TA 1.32b) |
| Beneish M = -3.51 (Cap -4..+1) = AAA |
As of July 14, 2026, the stock is trading at USD 8.01 with a total of 526,986 shares traded. Over the past week, the price has changed by -2.08%, over one month by -3.38%, over three months by -2.79% and over the past year by +9.73%.
Current recommended Stop Loss: 7.40 (which is 7.6% or 1.6 ATR below the current price).
Emergent Biosolutions has received a consensus analysts rating of 3.67. Therefore, it is recommended to hold EBS.
- StrongBuy: 1
- Buy: 1
- Hold: 0
- Sell: 1
- StrongSell: 0
| Analysts Target Price | 12 | 49.8% |
P/E Forward = 2.0773
P/S = 0.632
P/B = 0.8068
P/EG = 0.3835
Revenue TTM = 676.8m USD
EBIT TTM = 59.1m USD
EBITDA TTM = 154.5m USD
Long Term Debt = 573.6m USD (from longTermDebt, last quarter)
Short Term Debt = unknown (none)
Debt = 573.6m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 413.3m USD (calculated: Debt 573.6m - CCE 160.3m)
Enterprise Value = 841.0m USD (427.7m + Debt 573.6m - CCE 160.3m)
Interest Coverage Ratio = 1.06 (Ebit TTM 59.1m / Interest Expense TTM 55.6m)
EV/FCF = 6.21x (Enterprise Value 841.0m / FCF TTM 135.4m)
FCF Yield = 16.10% (FCF TTM 135.4m / Enterprise Value 841.0m)
FCF Margin = 20.01% (FCF TTM 135.4m / Revenue TTM 676.8m)
Net Margin = -1.27% (Net Income TTM -8.60m / Revenue TTM 676.8m)
Gross Margin = 44.44% ((Revenue TTM 676.8m - Cost of Revenue TTM 376.0m) / Revenue TTM)
Gross Margin QoQ = 43.31% (prev 31.34%)
Tobins Q-Ratio = 0.64 (Enterprise Value 841.0m / Total Assets 1.32b)
Interest Expense / Debt = 9.69% (Interest Expense 55.6m / Debt 573.6m)
Taxrate = 49.25% (6.60m / 13.4m)
NOPAT = 30.0m (EBIT 59.1m * (1 - 49.25%))
Current Ratio = 4.29 (Total Current Assets 637.6m / Total Current Liabilities 148.7m)
Debt / Equity = 1.10 (Debt 573.6m / totalStockholderEquity, last quarter 523.1m)
Debt / EBITDA = 2.68 (Net Debt 413.3m / EBITDA 154.5m)
Debt / FCF = 3.05 (Net Debt 413.3m / FCF TTM 135.4m)
Total Stockholder Equity = 541.1m (last 4 quarters mean from totalStockholderEquity)
RoA = -0.63% (Net Income -8.60m / Total Assets 1.32b)
RoE = -1.59% (Net Income TTM -8.60m / Total Stockholder Equity 541.1m)
RoCE = 5.30% (EBIT 59.1m / Capital Employed (Equity 541.1m + L.T.Debt 573.6m))
RoIC = 2.64% (NOPAT 30.0m / Invested Capital 1.14b)
WACC = 9.27% (E(427.7m)/V(1.00b) * Re(15.11%) + D(573.6m)/V(1.00b) * Rd(9.69%) * (1-Tc(0.49)))
Discount Rate = 15.11% (= CAPM, Blume Beta Adj.) -> capped to 13.17%
Shares (quarterly) Correlation: 55.35 | Cagr: 3.85%
[DCF] Terminal Value 75.04% ; FCFF base≈119.0m ; Y1≈136.4m ; Y5≈200.8m
[DCF] Fair Price = 42.36 (EV 2.60b - Net Debt 413.3m = Equity 2.19b / Shares 51.6m; r=9.27% [WACC]; 5y FCF grow 15.0% → 2.50% )
EPS Correlation: N/A | EPS CAGR: N/A | SUE: 0.45 | # QB: 0
Revenue Correlation: -86.91 | Revenue CAGR: -16.33% | SUE: -0.08 | # QB: 0
EPS current Quarter (2026-06-30): EPS=0.11 | Chg30d=+0.00% | Revisions=+0% | Analysts=1
EPS next Quarter (2026-09-30): EPS=0.35 | Chg30d=+40.00% | Revisions=+25% | Analysts=1
EPS current Year (2026-12-31): EPS=0.95 | Chg30d=+82.69% | Revisions=+25% | GrowthEPS=-37.9% | GrowthRev=-1.3%
EPS next Year (2027-12-31): EPS=0.91 | Chg30d=+264.00% | Revisions=+25% | GrowthEPS=+398.4% | GrowthRev=+21.7%